Beam Therapeutics (BEAM)

Executive Summary

Beam Therapeutics is a pioneering biotechnology company leveraging its proprietary base editing platform to develop precise genetic medicines. Unlike traditional CRISPR-Cas9, base editing enables single-letter DNA changes without double-strand breaks, offering potential advantages in safety and specificity. The company's pipeline spans hematology, oncology, and rare diseases, with lead candidates including BEAM-101 for sickle cell disease and beta-thalassemia (Phase 1/2), BEAM-201 for T-cell acute lymphoblastic leukemia/lymphoma (Phase 1/2), and BEAM-302 for alpha-1 antitrypsin deficiency (Phase 1/2). Beam is publicly traded on NASDAQ under the ticker BEAM and is headquartered in Cambridge, Massachusetts. Recent clinical progress includes ongoing dose escalation and expansion cohorts across multiple programs. Key upcoming milestones include initial efficacy readouts from the BEAM-101 sickle cell trial, which could validate base editing as a transformative modality. The company is also advancing BEAM-201, an allogeneic CAR-T therapy, and BEAM-302 for liver-targeted diseases. With a strong cash position and robust intellectual property, Beam is well-positioned to generate pivotal data over the next 12-18 months. However, execution risks remain given the early stage of base editing in humans and competitive pressures from other gene editing approaches.

Upcoming Catalysts (preview)

• H2 2026BEAM-101 Phase 1/2 interim efficacy data in sickle cell disease70% success
• Q4 2026BEAM-201 Phase 1/2 safety and preliminary efficacy data in T-ALL/LBL60% success
• H1 2027BEAM-302 Phase 1/2 proof-of-concept data in alpha-1 antitrypsin deficiency50% success